Beyond Air, Inc. (XAIR)
| Market Cap | 3.38M -72.0% |
| Revenue (ttm) | 7.69M +60.7% |
| Net Income | -33.49M |
| EPS | -62.88 |
| Shares Out | 957.63K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,543 |
| Open | 3.550 |
| Previous Close | 3.590 |
| Day's Range | 3.500 - 3.640 |
| 52-Week Range | 3.500 - 95.600 |
| Beta | 0.13 |
| Analysts | Buy |
| Price Target | 20.00 (+466.57%) |
| Earnings Date | Aug 13, 2026 |
About XAIR
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-h... [Read more]
Financial Performance
In fiscal year 2026, Beyond Air's revenue was $7.68 million, an increase of 107.26% compared to the previous year's $3.71 million. Losses were -$33.25 million, -28.69% less than in 2025.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for XAIR stock is "Buy." The 12-month stock price target is $20.0, which is an increase of 466.57% from the latest price.
News
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
GARDEN CITY, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (...
Beyond Air initiated with a Buy at Lake Street on durable recurring revenue
As previously reported, Lake Street initiated coverage of Beyond Air (XAIR) with a Buy rating and $10 price target The commercial-stage medical device company is built around LungFit, an inhaled…
Beyond Air initiated with a Buy at Lake Street
Lake Street analyst Frank Takkinen initiated coverage of Beyond Air (XAIR) with a Buy rating and $10 price target
Beyond Air gets Breakthrough Device Designation for LungFit GO
Beyond Air (XAIR) announced that the FDA has granted Breakthrough Device Designation to LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease.
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
GARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harness...
Beyond Air to sell NeuroNOS stake to Univo Pharmaceutical
Beyond Air (XAIR) announced that they have entered into a definitive agreement under which Univo Pharmaceutical Industries will acquire control over the outstanding shares of NeuroNOS Israel. The tran...
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone...
Beyond Air files to sell 5.42M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 5.42M shares of common stock. The company is not selling any…
Beyond Air Registration statement: Registration filing
Beyond Air filed a registration statement on August 17, 2026, providing details about a securities offering with the SEC.
Beyond Air Earnings Call Transcript: Q1 2027
Revenue remained flat at $1.8M, but gross margin improved to 13% and the commercial pipeline doubled. Guidance for 2026 is reaffirmed at $8M, with 2027 expected to exceed $16M pending FDA approval of Gen 2 LungFit PH. Recent financing strengthens the balance sheet.
Beyond Air Earnings release: Q1 2027
Beyond Air released its Q1 2027 earnings on August 13, 2026, summarizing the period's financial results.
Beyond Air Quarterly report: Q1 2027
Beyond Air has published its Q1 2027 quarterly earnings report on August 13, 2026.
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
GARDEN CITY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harness...
Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
GARDEN CITY, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harness...
Beyond Air trading halted, news pending
19:50 EDT Beyond Air (XAIR) trading halted, news pending
Beyond Air Earnings Call Transcript: Q4 2026
Revenue more than doubled to $7.7M in fiscal 2026, driven by strong LungFit PH adoption and high renewal rates. Guidance for 2026 is $8M, with 2027 expected to reach $16–18M, assuming Gen 2 approval and launch. Gen 2 is anticipated to significantly expand the addressable market.
Beyond Air Earnings release: Q4 2026
Beyond Air released its Q4 2026 earnings on June 26, 2026, summarizing the period's financial results.
Beyond Air Annual report: Q4 2026
Beyond Air has published its Q4 2026 annual report on June 26, 2026.
Beyond Air narrows FY26 revenue view to $8M from $8M-$10M, consensus $8.08M
“We are encouraged by the market interest in the second-generation LungFit PH system, which is currently under FDA review,” continued Goodman. “Subject to FDA approval, the system is designed to…
Beyond Air sees FY27 revenue $16M-$18M, consensus $12.7M
The company said, “For calendar year 2027, the Company announced revenue guidance of $16-$18 million, representing more than 110% year-over-year growth at the midpoint compared with 2026 guidance and ...
Beyond Air reports Q4 EPS (77c) vs. ($1.79) last year
Reports Q4 revenue $1.91M, consensus $2.3M. “Fiscal 2026 was a year of meaningful transition for Beyond Air (XAIR), marked by significant progress in strengthening the foundation of our LungFit PH…
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harness...
Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting
Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact informat...